Please assess the completion status of the following clinical trial:

Trial Title: Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 13.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, ages ≥18 years of age~* Subjects who are naive to HCV treatment, defined as no previous exposure to an Interferon (IFN), Ribavirin (RBV); or any HCV-specific direct acting antiviral or experimental therapy or subjects who are null responders to previous pegylated Interferon alfa (pegIFNα) plus Ribavirin (RBV) treatment~* Subjects should have chronic hepatitis C (CHC) as documented by:~  1. Positive for anti-HCV antibody, HCV RNA, or a positive HCV genotype test at least 6 months prior to screening, and positive for HCV RNA and Anti-HCV antibody at the time of screening, or~ 2. Positive for anti-HCV antibody and HCV RNA at the time of screening with a liver biopsy consistent with chronic HCV infection (or a liver biopsy performed prior to enrollment with evidence of CHC disease, such as the presence of fibrosis)~* HCV genotype 1a, 1b or 4 only~* HCV RNA viral load of ≥10,000 IU/mL at screening~* Have one of the following:~  1. Documented Fibrotest score of ≤0.72 and aspartate transferase (transminase) to platelet ratio index (APRI) ≤2; OR~ 2. Documented liver biopsy within 36 months preceding Day 1 showing absence of cirrhosis OR~ 3. Documented Fibroscan® ultrasound (where approved) within 12 months of screening showing absence of cirrhosis~* Body mass index (BMI) of 18.0 to 35.0 kg/m2, inclusive~* Subjects with compensated Child-Pugh A cirrhosis as documented by history of cirrhosis with any prior liver biopsy or Fibroscan® ultrasound (where approved) within 12 months prior to screening~Exclusion Criteria:~* Evidence of a medical condition associated with chronic liver disease other than HCV (such as but not limited to: hemochromatosis, autoimmune hepatitis,metabolic liver disease, alcoholic liver disease, toxin exposures)~* History of variceal bleeding, hepatic encephalopathy, or ascites requiring management with diuretics or paracentesis~* Current or known history of cancer (except in situ carcinoma of the cervix or adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior to enrollment~* Documented or suspected hepatocellular carcinoma (HCC)~* Positive for hepatitis B surface antigen (HBsAg)~* Positive for Human Immunodeficiency Virus-1 (HIV-1) and/or Human Immunodeficiency Virus-2 (HIV-2) antibodies~* Alanine transferase (transminase) (ALT) \>5x upper limit of normal (ULN)~* Total Bilirubin ≥2 mg/dL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg) (Type: EXPERIMENTAL): BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks~BMS-790052 60 mg tablet by mouth once daily for 24 Weeks~BMS 791325 75 mg table by mouth twice daily for 24 Weeks
- Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg) (Type: EXPERIMENTAL): BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 60 mg tablet by mouth once daily for 12 Weeks~BMS 791325 75 mg table by mouth twice daily for 12 Weeks
- Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg) (Type: EXPERIMENTAL): \* Contingent upon review of safety data from all available treated subjects from Groups 1 and 2~BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks~BMS-790052 60 mg tablet by mouth once daily for 24 Weeks~BMS 791325 150 mg table by mouth twice daily for 24 Weeks
- Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg) (Type: EXPERIMENTAL): \* Contingent upon review of safety data from all available treated subjects from Groups 1 and 2~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 60 mg tablet by mouth once daily for 12 Weeks~BMS 791325 150 mg table by mouth twice daily for 12 Weeks
- Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg) (Type: EXPERIMENTAL): \* Genotype 1 treatment-naive subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 75 mg table by mouth twice daily for 12 Weeks
- Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg) (Type: EXPERIMENTAL): \* Genotype 1 treatment-naive subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 150 mg table by mouth twice daily for 12 Weeks
- Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg) (Type: EXPERIMENTAL): \* Genotype 4 treatment-naive subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 75 mg table by mouth twice daily for 12 Weeks
- Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg) (Type: EXPERIMENTAL): \* Genotype 4 treatment-naive subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 150 mg table by mouth twice daily for 12 Weeks
- Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg) (Type: EXPERIMENTAL): \* Genotype 1 treatment-null/non-responder subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 75 mg table by mouth twice daily for 12 Weeks
- Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg) (Type: EXPERIMENTAL): \* Genotype 1 treatment-null/non-responder subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 150 mg table by mouth twice daily for 12 Weeks
- Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg) (Type: EXPERIMENTAL): \* Genotype 1 treatment-null/non-responder subjects~BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 24 Weeks~BMS 791325 75 mg table by mouth twice daily for 24 Weeks
- Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg) (Type: EXPERIMENTAL): \* Genotype 1 treatment-null/non-responder subjects~BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 24 Weeks~BMS 791325 150 mg table by mouth twice daily for 24 Weeks
- Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV (Type: EXPERIMENTAL): \* Genotype 1 treatment-naive subjects~BMS-650032 200 mg tablets orally twice daily 12 weeks~BMS-790052 30 mg tablets orally twice daily 12 weeks~BMS-791325 75 mg tablets orally twice daily 12 weeks~Ribavirin (RBV) tablets orally weight based dosing daily 12 weeks \[if subject is \< 75 kg: 1000 mg per day orally (2 x 200 mg tablets in AM and 3 x 200 mg tablets in PM), or if ≥ 75 kg: 1200 mg per day orally (3 x 200 mg tablets in AM and 3 x 200 mg tablets in PM\]

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete